Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/035958external-prioritypatent/WO2007033350A1/en
Application filed by Такеда Фармасьютикал Компани ЛимитедfiledCriticalТакеда Фармасьютикал Компани Лимитед
Publication of UA99112C2publicationCriticalpatent/UA99112C2/en
Pharmaceutical compositions comprising 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluorobenzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.
UAA200903416A2006-09-132007-09-11Use of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydr0-2h-pyrimidin-1-ylmethyl]-4-fluorobenzonitrile
UA99112C2
(en)
Compounds derived from quinazoline or pyrido [2,3-d] pyrimidine, autophagy inhibitors; pharmaceutical composition; and its use for the treatment of cancer, pancreatitis, neurodegeneration, among others.
Compounds derived from imidazo [1,2-a] pyridine; preparation procedure; pharmaceutical composition; intermediate compounds; and use in the treatment of cancer.
compound, pharmaceutical composition, methods for inhibiting the action of glycogen synthase kinase-3, and for treating, preventing or ameliorating a disease, use of a compound, and article of manufacture
Administration of 2-[[6-[(3r)-3-amino-l-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo- l(2h)-pyrimaidinyl]methyl]-benzonitrile for the treatment of conditions mediated with dipeptidyl peptidase inhibitors